Study identifier:SD-004-0377
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Once daily administration of 200 µg budesonide Turbuhaler and 200 µg fluticasone propionate via Diskus inhaler in stable asthmatics.
asthma
Phase 4
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|